TLPH icon

Talphera

0.6353 USD
+0.0178
2.88%
At close Dec 20, 4:00 PM EST
Pre-market
0.6529
+0.0176
2.77%
1 day
2.88%
5 days
-1.04%
1 month
-10.07%
3 months
-30.90%
6 months
-23.18%
Year to date
-14.20%
1 year
-15.85%
5 years
-98.56%
10 years
-99.53%
 

About: Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Employees: 15

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3% less funds holding

Funds holding: 30 [Q2] → 29 (-1) [Q3]

12.75% less ownership

Funds ownership: 37.33% [Q2] → 24.58% (-12.75%) [Q3]

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

37% less capital invested

Capital invested by funds: $5.64M [Q2] → $3.58M (-$2.07M) [Q3]

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9

Research analyst outlook

We haven’t received any recent analyst ratings for TLPH.

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - Chief Medical Officer Conference Call Participants James Molloy - Alliance Global Partners Thomas Yip - H.C. Wainwright Operator Welcome to the Talphera Third Quarter 2024 Financial Results Conference Call.
Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET  SAN MATEO, Calif. , Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update.
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Neutral
PRNewsWire
1 month ago
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
SAN MATEO, Calif. , Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m.
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
Neutral
PRNewsWire
2 months ago
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors.
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Neutral
PRNewsWire
3 months ago
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
SAN MATEO, Calif. , Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C.
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Neutral
PRNewsWire
4 months ago
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients completing the study after 72 hours Dr. Stuart Goldstein, a world-renowned nephrologist, is the first physician to enroll a patient in the NEPHRO CRRT study SAN MATEO, Calif. , Aug. 19, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEPHRO CRRT study.
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
Neutral
Seeking Alpha
4 months ago
Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript
Talphera, Inc. (NASDAQ:TLPH ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Founder and Chief Medical Officer Conference Call Participants Ed Arce - H.C. Wainwright Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Welcome to Talphera's Second Quarter 2024 Financial Results Conference Call.
Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript
Neutral
PRNewsWire
4 months ago
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June 30, 2024 of $14.0 million Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET SAN MATEO, Calif. , Aug. 14, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update.
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Neutral
PRNewsWire
4 months ago
Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
SAN MATEO, Calif. , Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2024 financial results after market close on Wednesday, August 14, 2024, then host a live webcast and conference call at 4:30 p.m.
Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
Neutral
PRNewsWire
7 months ago
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif. , May 20, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted inducement awards consisting of a non-statutory time-based stock option to purchase 185,000 shares of common stock and a time-based restricted stock unit award for 32,000 shares of common stock on May 20, 2024 to Dr. Shakil Aslam in connection with his appointment as the Chief Development Officer of Talphera in May 2024.
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Charts implemented using Lightweight Charts™